CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics (OTCBB: NVIV) congratulates Robert S. Langer, Sc.D., InVivo co-founder and member of the company’s scientific advisory board, for his selection as the recipient of the American Chemical Society’s (ACS) illustrious Priestley Medal for his distinguished services to chemistry. The Priestly Medal is the highest honor bestowed by the ACS, the world’s largest scientific society. Dr. Langer is the first chemical engineer to win the Priestley Medal in 65 years.
“Dr. Langer and I co-founded InVivo almost six years ago to create revolutionary treatments for spinal cord injury, but his inventions have become true platform technologies with the potential to affect many unmet medical conditions,” enthused Frank Reynolds, CEO of InVivo Therapeutics. Reynolds adds, “There is no one more deserving of this prestigious achievement.”
Dr. Langer, the David H. Koch Institute Professor at the Massachusetts Institute of Technology, is being honored in recognition of cutting-edge research that helped create the controlled-release drug industry and the field of tissue engineering. Dr. Langer’s research has resulted in a suite of patents for InVivo, a company dedicated to the development of groundbreaking technologies for the treatment of spinal cord injuries.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital.